1. Home
  2. JWSM vs AGEN Comparison

JWSM vs AGEN Comparison

Compare JWSM & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JWSM
  • AGEN
  • Stock Information
  • Founded
  • JWSM 2020
  • AGEN 1994
  • Country
  • JWSM United States
  • AGEN United States
  • Employees
  • JWSM N/A
  • AGEN N/A
  • Industry
  • JWSM Blank Checks
  • AGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • JWSM Finance
  • AGEN Health Care
  • Exchange
  • JWSM Nasdaq
  • AGEN Nasdaq
  • Market Cap
  • JWSM 302.5M
  • AGEN 125.8M
  • IPO Year
  • JWSM 2021
  • AGEN 2000
  • Fundamental
  • Price
  • JWSM $11.13
  • AGEN $6.13
  • Analyst Decision
  • JWSM
  • AGEN Buy
  • Analyst Count
  • JWSM 0
  • AGEN 3
  • Target Price
  • JWSM N/A
  • AGEN $37.33
  • AVG Volume (30 Days)
  • JWSM 7.9K
  • AGEN 1.2M
  • Earning Date
  • JWSM 01-01-0001
  • AGEN 08-06-2024
  • Dividend Yield
  • JWSM N/A
  • AGEN N/A
  • EPS Growth
  • JWSM 75.00
  • AGEN N/A
  • EPS
  • JWSM 0.28
  • AGEN N/A
  • Revenue
  • JWSM N/A
  • AGEN $161,416,000.00
  • Revenue This Year
  • JWSM N/A
  • AGEN $43.78
  • Revenue Next Year
  • JWSM N/A
  • AGEN N/A
  • P/E Ratio
  • JWSM $39.75
  • AGEN N/A
  • Revenue Growth
  • JWSM N/A
  • AGEN 69.94
  • 52 Week Low
  • JWSM $10.50
  • AGEN $4.78
  • 52 Week High
  • JWSM $11.25
  • AGEN $32.00
  • Technical
  • Relative Strength Index (RSI)
  • JWSM 54.05
  • AGEN 28.55
  • Support Level
  • JWSM $11.10
  • AGEN $5.64
  • Resistance Level
  • JWSM $11.14
  • AGEN $7.34
  • Average True Range (ATR)
  • JWSM 0.01
  • AGEN 1.32
  • MACD
  • JWSM 0.00
  • AGEN -1.16
  • Stochastic Oscillator
  • JWSM 75.00
  • AGEN 3.74

About JWSM Jaws Mustang Acquisition Corp.

Jaws Mustang Acquisition Corp is a blank check company. it is formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: